Ignite Creation Date:
2024-05-06 @ 3:07 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04529772
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2020-08-25
Brief Title:
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL ACE-LY-312
Sponsor:
Acerta Pharma BV
Organization:
Acerta Pharma BV
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Diffuse Large B-Cell Lymphoma |
Keywords:
| Name | View |
|---|---|
| Calquence | View |
| Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | View |
| Lymphoma | View |
| Lymphoma B-Cell | View |
| Lymphoma Large B-Cell Diffuse | View |
| Neoplasms | View |
| Lymphoproliferative Disorders | View |
| Lymphatic Diseases | View |
| Lymphoma Non-Hodgkin | View |
| Prednisone | View |
| Cyclophosphamide | View |
| Rituximab | View |
| Doxorubicin | View |
| Vincristine | View |
| Acalabrutinib | View |